Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days

X
Trial Profile

Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tripotassium dicitrato bismuthate/tetracycline/metronidazole (Primary) ; Amoxicillin; Clarithromycin; Omeprazole
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Adare Pharmaceuticals; Aptalis
  • Most Recent Events

    • 15 Mar 2012 This trial has been recruiting in France, United Kingdom and Spain and completed in Netherlands, Poland, Ireland and Italy.
    • 22 Feb 2011 Primary endpoint 'Helicobacter-pylori-eradication-rate' has been met, based on results published in Lancet.
    • 02 May 2010 Results were presented at Digestive Disease Week 2010.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top